Geode Capital Management
GMAB icon

Geode Capital Management’s Genmab GMAB Stock Holding History

Geode Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.81M Buy
65,711
+581
+0.9% +$15.4K ﹤0.01% 3213
2026
Q1 		$1.75M Buy
65,130
+18,369
+39% +$550K ﹤0.01% 3180
2025
Q4 		$1.44M Buy
46,761
+5,883
+14% +$183K ﹤0.01% 3271
2025
Q3 		$1.25M Buy
40,878
+13,751
+51% +$335K ﹤0.01% 3315
2025
Q2 		$560K Buy
27,127
+111
+0.4% +$2.28K ﹤0.01% 3521
2025
Q1 		$529K Sell
27,016
-16,695
-38% -$350K ﹤0.01% 3520
2024
Q4 		$912K Buy
43,711
+480
+1% +$10.5K ﹤0.01% 3411
2024
Q3 		$1.05M Sell
43,231
-80
-0.2% -$2.14K ﹤0.01% 3337
2024
Q2 		$1.09M Buy
43,311
+352
+0.8% +$9.98K ﹤0.01% 3272
2024
Q1 		$1.28M Buy
42,959
+1,583
+4% +$46.5K ﹤0.01% 3266
2023
Q4 		$1.32M Sell
41,376
-363
-0.9% -$11.4K ﹤0.01% 3237
2023
Q3 		$1.47M Buy
41,739
+24
+0.1% +$915 ﹤0.01% 3181
2023
Q2 		$1.59M Buy
41,715
+408
+1% +$16.3K ﹤0.01% 3185
2023
Q1 		$1.56M Sell
41,307
-535
-1% -$20.6K ﹤0.01% 3136
2022
Q4 		$1.77M Sell
41,842
-314
-0.7% -$12.9K ﹤0.01% 3096
2022
Q3 		$1.35M Buy
42,156
+648
+2% +$22.8K ﹤0.01% 3244
2022
Q2 		$1.35M Sell
41,508
-4,165
-9% -$135K ﹤0.01% 3285
2022
Q1 		$1.65M Sell
45,673
-22,267
-33% -$764K ﹤0.01% 3357
2021
Q4 		$2.69M Buy
67,940
+10,652
+19% +$444K ﹤0.01% 3227
2021
Q3 		$2.5M Buy
57,288
+8,678
+18% +$390K ﹤0.01% 3257
2021
Q2 		$1.99M Sell
48,610
-12,969
-21% -$500K ﹤0.01% 3268
2021
Q1 		$2.02M Buy
61,579
+8,312
+16% +$313K ﹤0.01% 3247
2020
Q4 		$2.17M Buy
53,267
+3,566
+7% +$133K ﹤0.01% 3041
2020
Q3 		$1.82M Buy
49,701
+8,177
+20% +$296K ﹤0.01% 2924
2020
Q2 		$1.41M Buy
41,524
+12,361
+42% +$337K ﹤0.01% 3026
2020
Q1 		$617K Buy
29,163
+11,455
+65% +$255K ﹤0.01% 3207
2019
Q4 		$395K Sell
17,708
-3,099
-15% -$67.6K ﹤0.01% 3578
2019
Q3 		$421K Buy
+20,807
New +$410K ﹤0.01% 3526

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management's GMAB Position: Q2 2026 in Review

Geode Capital Management increased its Genmab (GMAB) stake by 0.89% in Q2 2026, buying an estimated $15.4K and bringing the position to 65,711 shares worth $1.81M. The position accounts for ﹤0.01% of the portfolio, ranked #3213.

Geode Capital Management first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. The position peaked at $2.69M in Q4 2021. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Geode Capital Management held 65,711 shares of Genmab worth $1.81M as of Q2 2026.
  • Geode Capital Management bought 581 Genmab shares in Q2 2026, an estimated $15.4K.
  • Genmab made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3213 holding.
  • Geode Capital Management first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • Geode Capital Management's Genmab position peaked at $2.69M in Q4 2021.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.